Results 41 to 50 of about 71,479 (314)

Updated Perspectives on the Diagnosis and Management of Onychomycosis

open access: yesClinical, Cosmetic and Investigational Dermatology, 2022
Julianne M Falotico,1 Shari R Lipner2 1Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA; 2Weill Cornell Medicine, Department of Dermatology, New York, NY, USACorrespondence: Shari R Lipner, Weill Cornell Medicine, Department
Falotico JM, Lipner SR
doaj  

Histopathology of Nail Diseases

open access: yesJournal of Investigative Dermatology, 1952
The difficulties encountered in attempting to delineate the accurate diagnosis in nail dyscrasias are well known. Where the glabrous skin is involved in a cu- taneous syndrome, the nail condition is assumed to be part of the same disorder. Practically all textbook descriptions are based on this assumption except in fungous infections where the fungi ...
White, Cleveland J., Laipply, Thomas C.
openaire   +2 more sources

Inhibiting stearoyl‐CoA desaturase suppresses bone metastatic prostate cancer by modulating cellular stress, mTOR signaling, and DNA damage response

open access: yesFEBS Letters, EarlyView.
Bone metastasis in prostate cancer (PCa) patients is a clinical hurdle due to the poor understanding of the supportive bone microenvironment. Here, we identify stearoyl‐CoA desaturase (SCD) as a tumor‐promoting enzyme and potential therapeutic target in bone metastatic PCa.
Alexis Wilson   +7 more
wiley   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham   +21 more
wiley   +1 more source

Twenty nail onychomadesis following acute viral hepatitis B infection

open access: yesJournal of Marine Medical Society, 2020
Onychomadesis is a nail plate abnormality with temporary cessation in the growth of the nail plate due to disturbances in the nail matrix. Any local or systemic condition affecting the nail matrix directly or indirectly can lead to onychomadesis.
M Sivasankari, Preema Sinha
doaj   +1 more source

POS0025 COMBINED NAILFOLD CAPILLAROSCOPY AND ULTRASONOGRAPHY OF THE NAIL-ENTHESIS COMPLEX TO DISCRIMINATE PSORIATIC DISEASE FROM RHEUMATOID ARTHRITIS PATIENTS AND HEALTHY SUBJECTS [PDF]

open access: bronze, 2023
Giacomo Cafaro   +6 more
openalex   +1 more source

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira   +14 more
wiley   +1 more source

Onychogryphosis in tuberous sclerosis complex: an unusual feature [PDF]

open access: yesAnais Brasileiros de Dermatologia, 2016
Onychogryphosis is an acquired nail plate change. It often affects the toenail and is characterized by an opaque, yellow-brownish nail plate that is distorted, grossly thickened, elongated, and partly curved resembling a ram's horn.
Xiang-chun Han   +2 more
doaj   +1 more source

Modeling hepatic fibrosis in TP53 knockout iPSC‐derived human liver organoids

open access: yesMolecular Oncology, EarlyView.
This study developed iPSC‐derived human liver organoids with TP53 gene knockout to model human liver fibrosis. These organoids showed elevated myofibroblast activation, early disease markers, and advanced fibrotic hallmarks. The use of profibrotic differentiation medium further amplified the fibrotic signature seen in the organoids.
Mustafa Karabicici   +8 more
wiley   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

open access: yesMolecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy